UPDATE: Innate seeks $11m in IPO to support lead MS candidate
This article was originally published in Scrip
Innate Immunotherapeutics is looking to raise up to AUD12m ($11m) before costs through the public offer of up to 60m shares at AUD0.20 each to progress the development of a novel therapy for serious multiple sclerosis.
You may also be interested in...
While it was not as affected as some other countries, Japan still had the pandemic to deal with and regulators responded while managing to keep up regular product review work, including several world-first approvals. Coronavirus vaccine roll-outs and the first general annual reimbursement price cut are on the cards for this year.
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.